NEW YORK (GenomeWeb) – Cambridge Epigenetix and NuGen Technologies have partnered to integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.

The companies said that the agreement will enable Cambridge to focus on its epigenetic biomarker discovery programs, both in house and in partnership with biopharma companies, while strengthening NuGen's whole-genome and targeted enrichment systems for epigenetic sequencing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.